Covered recipient · General Payments record
ROY TIMOTHY WEBB
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$907.70
59 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $907.70 | 59 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $174.71 | 12 |
| AstraZeneca Pharmaceuticals LP | $66.87 | 5 |
| Incyte Corporation | $64.58 | 4 |
| Astellas Pharma US Inc | $59.03 | 3 |
| Karyopharm Therapeutics Inc. | $55.25 | 3 |
| Lilly USA, LLC | $46.62 | 3 |
| GENZYME CORPORATION | $45.75 | 3 |
| Genentech USA, Inc. | $44.24 | 3 |
| Novartis Pharmaceuticals Corporation | $43.00 | 2 |
| Merck Sharp & Dohme Corporation | $40.16 | 3 |
| Kite Pharma, Inc. | $39.08 | 3 |
| Seagen Inc. | $33.19 | 2 |
| Clovis Oncology, Inc. | $32.46 | 2 |
| Janssen Biotech, Inc. | $20.17 | 1 |
| Regeneron Healthcare Solutions, Inc. | $17.66 | 1 |
| ARRAY BIOPHARMA INC | $16.98 | 1 |
| Janssen Pharmaceuticals, Inc | $16.68 | 1 |
| EMD Serono, Inc. | $15.67 | 1 |
| AbbVie Inc. | $14.67 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $12.78 | 1 |
| Dova Pharmaceuticals | $12.71 | 1 |
| PFIZER INC. | $11.99 | 1 |
| BeiGene USA, Inc. | $11.95 | 1 |
| Exelixis Inc. | $11.50 | 1 |
Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ROY TIMOTHY WEBB
NPI 1346227048 · CMS profile ID 288306
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
HOT SPRINGS, AR
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1346227048?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ROY TIMOTHY WEBB, NPI 1346227048, CMS profile ID 288306. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346227048?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). ROY TIMOTHY WEBB, NPI 1346227048, CMS profile ID 288306. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346227048?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- ROY TIMOTHY WEBB, NPI 1346227048, CMS profile ID 288306, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1346227048?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
59 matching records · $907.70 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–59 of 59.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| ARRAY BIOPHARMA INC | $16.98 | 01/31/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743739729 | CMS |
| Kite Pharma, Inc. | $15.02 | 01/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 731502999 | CMS |
| Genentech USA, Inc. | $21.31 | 01/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743098175 | CMS |
| Genentech USA, Inc. | $11.87 | 01/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743098169 | CMS |
| PFIZER INC. | $11.99 | 01/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743134735 | CMS |
| Regeneron Healthcare Solutions, Inc. | $17.66 | 01/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 724464337 | CMS |
| Novartis Pharmaceuticals Corporation | $21.82 | 01/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726180639 | CMS |
| Dova Pharmaceuticals | $12.71 | 01/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 752350653 | CMS |
| Lilly USA, LLC | $13.53 | 01/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728626537 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $238,104.93 | 9 |
| PY2024 | Principal investigator | $50,194.93 | 7 |
| PY2023 | Principal investigator | $39,390.00 | 15 |
| PY2022 | Principal investigator | $71,071.00 | 15 |
| PY2021 | Principal investigator | $6,530.00 | 19 |
| PY2020 | Principal investigator | $12,451.52 | 34 |
| PY2019 | Principal investigator | $20,457.49 | 53 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
9 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $2,625.00 | 08/21/2025 | Non-covered Recipient Entity Multiple Doctors | Connect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients. | No dispute reported | 06/30/2026 | 1235995535 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $29,128.33 | 05/31/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY NETWORK, LLC | a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer | No dispute reported | 06/30/2026 | 1185549185 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $25,873.32 | 05/31/2025 | Non-covered Recipient Entity AMERICAN ONCOLOGY NETWORK, LLC | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) | No dispute reported | 06/30/2026 | 1185549187 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $44,061.65 | 05/30/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer | No dispute reported | 06/30/2026 | 1185549191 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $39,915.00 | 05/22/2025 | Non-covered Recipient Entity Genesis Cancer And Blood Institute Hot Springs | Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) | No dispute reported | 06/30/2026 | 1235997177 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $20,546.90 | 05/09/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) | No dispute reported | 06/30/2026 | 1185549181 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $335.93 | 03/25/2025 | Non-covered Recipient Entity Genesis Cancer And Blood Institute Hot Springs | Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) | No dispute reported | 06/30/2026 | 1235997175 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $43,300.00 | 01/24/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer | No dispute reported | 06/30/2026 | 1185549183 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $32,318.80 | 01/03/2025 | Non-covered Recipient Entity SARAH CANNON RESEARCH INSTITUTE LLC | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) | No dispute reported | 06/30/2026 | 1185549189 |